Literature DB >> 8382514

Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer.

C R Lee1, P W Nicholson, R L Souhami, M L Slevin, M R Hall, A A Deshmukh.   

Abstract

Using an 'intelligent' tablet bottle which, unknown to the patient, electronically records the times of opening we have assessed the compliance of patients with prescribed oral medication. The compliance pattern of 12 patients receiving low dose etoposide for small cell lung cancer was monitored over 25 treatment periods, representing a total of 298 days. The data were expressed as overall compliance (OC), defined as the observed number of bottle openings as a percentage of the prescribed number of doses, and as two indices representing daily and hourly irregularities in the times of opening. The OC had a mean (+/- s.d.) value of 93.2% (+/- 12%) over the 25 treatment periods, and is similar to that which we have reported in a group of lymphoma patients (Lee et al., 1992). By means of a self assessed diary card we monitored the physical and mental state of the patients. Although we found significant associations between the compliance measures and some of the diary card measures, the magnitude of the observed effects would be of little practical consequence. We conclude that, in our group of patients, inadequate compliance with oral chemotherapy would not account for any significant lack of clinical response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8382514      PMCID: PMC1968272          DOI: 10.1038/bjc.1993.115

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  Electronic monitor for patient compliance with drug therapy.

Authors:  P W Nicholson
Journal:  Med Biol Eng Comput       Date:  1991-11       Impact factor: 2.602

2.  Low-dose oral etoposide: a new role for an old drug?

Authors:  M L Slevin
Journal:  J Clin Oncol       Date:  1990-10       Impact factor: 44.544

3.  Patient compliance with oral chemotherapy as assessed by a novel electronic technique.

Authors:  C R Lee; P W Nicholson; R L Souhami; A A Deshmukh
Journal:  J Clin Oncol       Date:  1992-06       Impact factor: 44.544

4.  Compliance with oral drug therapy in patients with hematologic malignancy.

Authors:  A M Levine; J L Richardson; G Marks; K Chan; J Graham; J N Selser; C Kishbaugh; D R Shelton; C A Johnson
Journal:  J Clin Oncol       Date:  1987-09       Impact factor: 44.544

5.  Quality of life during chemotherapy for small cell lung cancer: assessment and use of a daily diary card in a randomized trial.

Authors:  D M Geddes; L Dones; E Hill; K Law; P G Harper; S G Spiro; J S Tobias; R L Souhami
Journal:  Eur J Cancer       Date:  1990-04       Impact factor: 9.162

6.  Daily oral etoposide in the treatment of cancer.

Authors:  L H Einhorn
Journal:  Semin Oncol       Date:  1991-02       Impact factor: 4.929

7.  Patient noncompliance with self-administered chemotherapy.

Authors:  A H Lebovits; J J Strain; S J Schleifer; J S Tanaka; S Bhardwaj; M R Messe
Journal:  Cancer       Date:  1990-01-01       Impact factor: 6.860

Review 8.  Chronic oral etoposide.

Authors:  F A Greco; D H Johnson; J D Hainsworth
Journal:  Cancer       Date:  1991-01-01       Impact factor: 6.860

Review 9.  The pharmacology of intravenous and oral etoposide.

Authors:  D N Carney
Journal:  Cancer       Date:  1991-01-01       Impact factor: 6.860

10.  Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public.

Authors:  M L Slevin; L Stubbs; H J Plant; P Wilson; W M Gregory; P J Armes; S M Downer
Journal:  BMJ       Date:  1990-06-02
  10 in total
  10 in total

Review 1.  Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer.

Authors:  J Andrew Skirvin; Stuart M Lichtman
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 2.  Oral antineoplastic agents: how do we care about adherence?

Authors:  Marie Barillet; Virginie Prevost; Florence Joly; Bénédicte Clarisse
Journal:  Br J Clin Pharmacol       Date:  2015-10-28       Impact factor: 4.335

Review 3.  Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature.

Authors:  Krishna Patel; Nathan R Foster; Ann Farrell; Nguyet Anh Le-Lindqwister; Josy Mathew; Brian Costello; John Reynolds; Jeffrey P Meyers; Aminah Jatoi
Journal:  J Cancer Educ       Date:  2013-12       Impact factor: 2.037

Review 4.  Oral chemotherapy agents in the treatment of leukaemia.

Authors:  R B Geller; S P Dix
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 5.  Oral anticancer drugs in the elderly: an overview.

Authors:  Sara Lonardi; Alberto Bortolami; Micaela Stefani; Silvio Monfardini
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

6.  Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.

Authors:  Sven Simons; Susanne Ringsdorf; Michael Braun; Ulrich J Mey; Peter F Schwindt; Yon D Ko; Ingo Schmidt-Wolf; Walther Kuhn; Ulrich Jaehde
Journal:  Support Care Cancer       Date:  2010-06-16       Impact factor: 3.603

Review 7.  Oral cancer treatment: developments in chemotherapy and beyond.

Authors:  V J O'Neill; C J Twelves
Journal:  Br J Cancer       Date:  2002-10-21       Impact factor: 7.640

8.  Impacts of a navigation program based on health information technology for patients receiving oral anticancer therapy: the CAPRI randomized controlled trial.

Authors:  Chloé Gervès-Pinquié; Fatima Daumas-Yatim; Benoît Lalloué; Anne Girault; Marie Ferrua; Aude Fourcade; François Lemare; Mario Dipalma; Etienne Minvielle
Journal:  BMC Health Serv Res       Date:  2017-02-13       Impact factor: 2.655

Review 9.  Pharmacological factors influencing anticancer drug selection in the elderly.

Authors:  Veena John; Sandeep Mashru; Stuart Lichtman
Journal:  Drugs Aging       Date:  2003       Impact factor: 4.271

10.  Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.

Authors:  M T Seymour; J L Mansi; C J Gallagher; M E Gore; P G Harper; T R Evans; P M Edmonds; M L Slevin
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.